Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for cystic fibrosis-related diabetes
ACTRN12625001438448Phase 4Recruiting
- Sponsor
- Western Sydney Local Health District
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in cystic fibrosis-related diabetes (CFRD) comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Change in glycaemia and Change in body mass index. Started Aug 2026; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
cystic fibrosis-related diabetes (CFRD)
Beyond the preview
Go deeper on ACTRN12625001438448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001438448.